Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Advertisement
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
Omidubicel-onlv is a “substantially modified” allogeneic cord blood-based cell therapy.
Dr. June has made “seminal contributions” to CAR T-cell therapy for blood cancers,
Nearly half of caregivers reported a high use of approach-oriented coping strategies.
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
The study used natural language processing for computer-assisted review of electronic health records.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.